BP897
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530471

CAS#: 314776-92-6

Description: BP897 is a potent (K(i) = 0.92 nM) dopamine D(3) receptor compound developed for the treatment of cocaine abuse and craving. BP 897 has a high selectivity for the dopamine D(3) versus D(2) receptors (70-fold) and a moderate affinity for 5-HT(1A) receptors, (K(i) = 84 nM), adrenergic-alpha(1) (K(i) = 60 nM) and -alpha(2) adrenoceptors (K(i) = 83 nM). BP 897 displays significant intrinsic activity at the human dopamine D(3) receptor by decreasing forskolin-stimulated cAMP levels and by stimulating mitogenesis of dopamine D(3)-expressing NG108-15 cells.


Chemical Structure

img
BP897
CAS# 314776-92-6

Theoretical Analysis

MedKoo Cat#: 530471
Name: BP897
CAS#: 314776-92-6
Chemical Formula: C26H31N3O2
Exact Mass: 417.24
Molecular Weight: 417.553
Elemental Analysis: C, 74.79; H, 7.48; N, 10.06; O, 7.66

Price and Availability

Size Price Availability Quantity
50mg USD 350
100mg USD 550
200mg USD 950
500mg USD 1650
1g USD 2750
2g USD 4350
5g USD 6950
Bulk inquiry

Synonym: BP897; BP-897; BP 897.

IUPAC/Chemical Name: N-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-2-naphthamide

InChi Key: MNHDKMDLOJSCGN-UHFFFAOYSA-N

InChi Code: InChI=1S/C26H31N3O2/c1-31-25-11-5-4-10-24(25)29-18-16-28(17-19-29)15-7-6-14-27-26(30)23-13-12-21-8-2-3-9-22(21)20-23/h2-5,8-13,20H,6-7,14-19H2,1H3,(H,27,30)

SMILES Code: O=C(NCCCCN1CCN(C2=CC=CC=C2OC)CC1)C3=CC=C4C=CC=CC4=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 417.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Visanji NP, Millan MJ, Brotchie JM. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats. Exp Neurol. 2006 Nov;202(1):85-92. PubMed PMID: 16814282.

2: Hsu A, Togasaki DM, Bezard E, Sokoloff P, Langston JW, Di Monte DA, Quik M. Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther. 2004 Nov;311(2):770-7. PubMed PMID: 15226382.

3: Cook CD, Newman JL, Winfree JC, Beardsley PM. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice. Pharmacol Biochem Behav. 2004 Feb;77(2):309-18. PubMed PMID: 14751459.

4: Cervo L, Carnovali F, Stark JA, Mennini T. Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors. Neuropsychopharmacology. 2003 Jun;28(6):1150-9. PubMed PMID: 12700684.

5: Narendran R, Slifstein M, Guillin O, Hwang Y, Hwang DR, Scher E, Reeder S, Rabiner E, Laruelle M. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Synapse. 2006 Dec 1;60(7):485-95. PubMed PMID: 16952157.

6: Nebel N, Maschauer S, Kuwert T, Hocke C, Prante O. In Vitro and In Vivo Characterization of Selected Fluorine-18 Labeled Radioligands for PET Imaging of the Dopamine D3 Receptor. Molecules. 2016 Aug 29;21(9). pii: E1144. doi: 10.3390/molecules21091144. PubMed PMID: 27589704.

7: Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors. Eur J Pharmacol. 2009 Apr 1;607(1-3):35-40. doi: 10.1016/j.ejphar.2009.02.007. PubMed PMID: 19217900.

8: Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33. doi: 10.1016/j.ejphar.2008.09.008. PubMed PMID: 18831971.

9: Hocke C, Cumming P, Maschauer S, Kuwert T, Gmeiner P, Prante O. Biodistribution studies of two 18F-labeled pyridinylphenyl amides as subtype selective radioligands for the dopamine D3 receptor. Nucl Med Biol. 2014 Mar;41(3):223-8. doi: 10.1016/j.nucmedbio.2013.12.014. PubMed PMID: 24480780.

10: Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R. Direct and indirect interactions of the dopamine D₃ receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn Schmiedebergs Arch Pharmacol. 2013 Feb;386(2):107-24. doi: 10.1007/s00210-012-0797-0. PubMed PMID: 23001156; PubMed Central PMCID: PMC3558669.

11: Polakowski JS, Segreti JA, Cox BF, Hsieh GC, Kolasa T, Moreland RB, Brioni JD. Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats. Clin Exp Pharmacol Physiol. 2004 Dec;31(12):837-41. PubMed PMID: 15659045.

12: Cook CD, Beardsley PM. Modulation of the discriminative stimulus effects of mu opioid agonists in rats: I. Effects of dopamine D2/3 antagonists. Behav Pharmacol. 2004 Feb;15(1):65-74. PubMed PMID: 15075628.

13: Gao M, Wang M, Hutchins GD, Zheng QH. Synthesis of new carbon-11-labeled carboxamide derivatives as potential PET dopamine D3 receptor radioligands. Appl Radiat Isot. 2008 Dec;66(12):1891-7. doi: 10.1016/j.apradiso.2008.05.010. PubMed PMID: 18602269.

14: Cook CD, Beardsley PM. The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice. Pharmacol Biochem Behav. 2003 May;75(2):363-71. PubMed PMID: 12873628.

15: Millan MJ, Iob L, Péglion JL, Dekeyne A. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors. Psychopharmacology (Berl). 2007 Apr;191(3):767-82. PubMed PMID: 17047933.

16: Francès H, Le Foll B, Diaz J, Smirnova M, Sokoloff P. Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice. Neuroreport. 2004 Oct 5;15(14):2245-9. PubMed PMID: 15371743.

17: Campiani G, Butini S, Trotta F, Fattorusso C, Catalanotti B, Aiello F, Gemma S, Nacci V, Novellino E, Stark JA, Cagnotto A, Fumagalli E, Carnovali F, Cervo L, Mennini T. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. J Med Chem. 2003 Aug 28;46(18):3822-39. PubMed PMID: 12930145.

18: Bettinetti L, Schlotter K, Hübner H, Gmeiner P. Interactive SAR studies: rational discovery of super-potent and highly selective dopamine D3 receptor antagonists and partial agonists. J Med Chem. 2002 Oct 10;45(21):4594-7. PubMed PMID: 12361386.